<DOC>
	<DOCNO>NCT01795573</DOCNO>
	<brief_summary>Clinical trial allospecific regulatory cell ( Tregs ) prevention acute graft-versus-host disease ( GVHD ) human leukocyte antigen ( HLA ) identical sibling transplant .</brief_summary>
	<brief_title>Ex-vivo Expanded Donor Regulatory T Cells Prevention Acute Graft-Versus-Host Disease</brief_title>
	<detailed_description>To evaluate safety sirolimus base immune suppression ex-vivo expand donor regulatory T cell prevention acute graft-versus-host disease follow allogeneic hematopoietic cell transplantation .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Signed informed consent Diagnoses : a. Hematologic malignancy Acute myelogenous leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , myelodysplastic syndrome ( MDS ) , chronic lymphocytic leukemia ( CLL ) , nonHodgkin lymphoma ( NHL ) , Hodgkin lymphoma ( HL ) , multiple myeloma ( MM ) complete remission ( CR ) . Complete remission define per morphologic , cytogenetic , FISH , molecular , radiographic image study appropriate condition list . AML , ALL : Normal value absolute neutrophil count ( &gt; 1000/microL ) platelet count ( &gt; 100,000/microL ) ; Absence extramedullary leukemia ; Less 5 percent blast cell present bone marrow MDS : Bone marrow ≤5 percent myeloblast normal maturation cell line ; Peripheral blood demonstrate hemoglobin ≥11 g/dL , platelet ≥100 x 10^9/L , neutrophil ≥1 x 10^9/L , circulate blast CLL : Absence constitutional symptom attributable CLL ; No lymph node &gt; 1.5 cm diameter compute tomography ; No hepatomegaly splenomegaly compute tomography ; Absolute neutrophil count &gt; 1500/microL ; Platelet count &gt; 100,000/microL ; No clonal lymphocytes peripheral blood immunophenotyping ; Bone marrow evidence clonal CLL ( flow cytometry and/or immunohistochemistry NHL : No clinical evidence disease diseaserelated symptom ; Typically FDGavid lymphoma : posttreatment residual mass size permit long PET negative ; Variably FDGavid lymphoma/FDG avidity unknown : lymph node normal size CT ; Spleen liver nonpalpable without nodule ; If pretreatment bone marrow biopsy positive , repeat bone marrow biopsy must negative ; morphologically indeterminate , immunohistochemistry negative If pretreatment bone marrow biopsy positive , repeat bone marrow biopsy must negative ; morphologically indeterminate , immunohistochemistry negative HL : No clinical evidence disease diseaserelated symptom ; A posttreatment residual mass size permit long PET negative ; Spleen liver must nonpalpable without nodule ; If pretreatment bone marrow biopsy positive , adequate bone marrow biopsy site must clear infiltrate ; indeterminate morphology , immunohistochemistry negative MM : Absence monoclonal protein serum urine immunofixation current evidence soft tissue plasmacytoma ; Bone marrow aspirate biopsy must demonstrate less 5 percent clonal plasma cell ; In patient lack measurable M proteins serum urine monitor use FLC level , definition CR require normalization free light chain ( FLC ) ratio addition criterion MDS : May achieve CR either hypomethylating agent therapy , induction chemotherapy , therapy MDS : Low/intermediate1 IPSS risk category patient eligible fail prior therapy transfusiondependent Peripheral blood white blood count ( WBC ) great 2,000 per microliter ( require collection dendritic cell precursor ) Adequate vital organ function : Left ventricular ejection fraction ( LVEF ) ≥ 45 % multigated acquisition ( MUGA ) scan echocardiogram ; Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , diffuse lung capacity oxygenation ( DLCO ) ≥ 50 % predict value pulmonary function test ; Transaminases ( AST , ALT ) &lt; 3 time upper limit normal value ; Creatinine clearance ≥ 50cc/min Infectious disease criterion : No active infection ; infection control antimicrobial therapy exclude HIV negative ELISA reverse transcription polymerase chain reaction ( RTPCR ) [ ELISA positive RTPCR negative , ELISA consider false positive ] Hepatitis B C negative serology RTPCR Must complete full screening panel : HIV 1 , 2 serology RTPCR ; human T cell lymphotropic virus type 1/2 ( HTLV1/2 ) serology ; rapid plasma reagin ( RPR ) serology ; EpsteinBarr virus ( EBV ) serology ; Cytomegalovirus ( CMV ) serology ; herpes simplex virus ( HSV ) serology ; Varicella . Zoster Virus ( VZV ) serology Performance status : Karnofsky Performance Status Score ≥ 60 % . Agreement utilize effective contraceptive method study ( one year ) Eligible donor include sibling age ≥ 18 matched recipient HLAA , B , C , DRB1 Those Sorror 's comorbidity factor score &gt; 3 2 Sorror 's factor composite score ≥ 3 Important modification comorbidity index calculation . DLCO include assessment pulmonary risk , except DLCO &lt; 50 % , merit score 3 thereby exclude trial . Antithymocyte globulin ( ATG ) part condition regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>GVHD</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
	<keyword>CLL</keyword>
	<keyword>NHL</keyword>
	<keyword>HL</keyword>
	<keyword>MM</keyword>
</DOC>